Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23


Proof-of-Principle for Immune Control of Global HIV-1 Reactivation In Vivo.

Smith NM, Mlcochova P, Watters SA, Aasa-Chapman MM, Rabin N, Moore S, Edwards SG, Garson JA, Grant PR, Ferns RB, Kashuba A, Mayor NP, Schellekens J, Marsh SG, McMichael AJ, Perelson AS, Pillay D, Goonetilleke N, Gupta RK.

Clin Infect Dis. 2015 Jul 1;61(1):120-8. doi: 10.1093/cid/civ219. Epub 2015 Mar 16.


Protease inhibitors effectively block cell-to-cell spread of HIV-1 between T cells.

Titanji BK, Aasa-Chapman M, Pillay D, Jolly C.

Retrovirology. 2013 Dec 24;10:161. doi: 10.1186/1742-4690-10-161.


Relative resistance of HIV-1 founder viruses to control by interferon-alpha.

Fenton-May AE, Dibben O, Emmerich T, Ding H, Pfafferott K, Aasa-Chapman MM, Pellegrino P, Williams I, Cohen MS, Gao F, Shaw GM, Hahn BH, Ochsenbauer C, Kappes JC, Borrow P.

Retrovirology. 2013 Dec 3;10:146. doi: 10.1186/1742-4690-10-146.


A gp41 MPER-specific llama VHH requires a hydrophobic CDR3 for neutralization but not for antigen recognition.

Lutje Hulsik D, Liu YY, Strokappe NM, Battella S, El Khattabi M, McCoy LE, Sabin C, Hinz A, Hock M, Macheboeuf P, Bonvin AM, Langedijk JP, Davis D, Forsman Quigley A, Aasa-Chapman MM, Seaman MS, Ramos A, Poignard P, Favier A, Simorre JP, Weiss RA, Verrips CT, Weissenhorn W, Rutten L.

PLoS Pathog. 2013 Mar;9(3):e1003202. doi: 10.1371/journal.ppat.1003202. Epub 2013 Mar 7.


Llama antibody fragments recognizing various epitopes of the CD4bs neutralize a broad range of HIV-1 subtypes A, B and C.

Strokappe N, Szynol A, Aasa-Chapman M, Gorlani A, Forsman Quigley A, Hulsik DL, Chen L, Weiss R, de Haard H, Verrips T.

PLoS One. 2012;7(3):e33298. doi: 10.1371/journal.pone.0033298. Epub 2012 Mar 15.


Vaccination with coxsackievirus B3 virus-like particles elicits humoral immune response and protects mice against myocarditis.

Zhang L, Parham NJ, Zhang F, Aasa-Chapman M, Gould EA, Zhang H.

Vaccine. 2012 Mar 16;30(13):2301-8. doi: 10.1016/j.vaccine.2012.01.061. Epub 2012 Jan 31.


Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes.

de Silva TI, Aasa-Chapman M, Cotten M, Hué S, Robinson J, Bibollet-Ruche F, Sarge-Njie R, Berry N, Jaye A, Aaby P, Whittle H, Rowland-Jones S, Weiss R.

J Virol. 2012 Jan;86(2):930-46. doi: 10.1128/JVI.06126-11. Epub 2011 Nov 9.


In vivo emergence of HIV-1 highly sensitive to neutralizing antibodies.

Aasa-Chapman MM, Cheney KM, Hué S, Forsman A, O'Farrell S, Pellegrino P, Williams I, McKnight Á.

PLoS One. 2011;6(8):e23961. doi: 10.1371/journal.pone.0023961. Epub 2011 Aug 24.


Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection.

Willey S, Aasa-Chapman MM, O'Farrell S, Pellegrino P, Williams I, Weiss RA, Neil SJ.

Retrovirology. 2011 Mar 14;8:16. doi: 10.1186/1742-4690-8-16.


Modulation of HIV-1 macrophage-tropism among R5 envelopes occurs before detection of neutralizing antibodies.

Richards KH, Aasa-Chapman MM, McKnight A, Clapham PR.

Retrovirology. 2010 May 27;7:48. doi: 10.1186/1742-4690-7-48.


Novel subtype C human immunodeficiency virus type 1 envelopes cloned directly from plasma: coreceptor usage and neutralization phenotypes.

Koh WW, Forsman A, Hué S, van der Velden GJ, Yirrell DL, McKnight A, Weiss RA, Aasa-Chapman MM.

J Gen Virol. 2010 Sep;91(Pt 9):2374-80. doi: 10.1099/vir.0.022228-0. Epub 2010 May 19.


Generation of a family-specific phage library of llama single chain antibody fragments that neutralize HIV-1.

Koh WW, Steffensen S, Gonzalez-Pajuelo M, Hoorelbeke B, Gorlani A, Szynol A, Forsman A, Aasa-Chapman MM, de Haard H, Verrips T, Weiss RA.

J Biol Chem. 2010 Jun 18;285(25):19116-24. doi: 10.1074/jbc.M110.116699. Epub 2010 Apr 16.


Humoral immunity to HIV-1: neutralisation and antibody effector functions.

Willey S, Aasa-Chapman MM.

Trends Microbiol. 2008 Dec;16(12):596-604. doi: 10.1016/j.tim.2008.08.008. Epub 2008 Oct 27. Review.


Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120.

Forsman A, Beirnaert E, Aasa-Chapman MM, Hoorelbeke B, Hijazi K, Koh W, Tack V, Szynol A, Kelly C, McKnight A, Verrips T, de Haard H, Weiss RA.

J Virol. 2008 Dec;82(24):12069-81. doi: 10.1128/JVI.01379-08. Epub 2008 Oct 8.


Mapping the immune response to the outer domain of a human immunodeficiency virus-1 clade C gp120.

Chen H, Xu X, Lin HH, Chen SH, Forsman A, Aasa-Chapman M, Jones IM.

J Gen Virol. 2008 Oct;89(Pt 10):2597-604. doi: 10.1099/vir.0.2008/003491-0.


Clade specific neutralising vaccines for HIV: an appropriate target?

McKnight A, Aasa-Chapman MM.

Curr HIV Res. 2007 Nov;5(6):554-60. Review.


A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy.

Hardy GA, Imami N, Nelson MR, Sullivan AK, Moss R, Aasa-Chapman MM, Gazzard B, Gotch FM.

J Immune Based Ther Vaccines. 2007 Apr 11;5:6. doi: 10.1186/1476-8518-5-6.


Novel envelope determinants for CCR3 use by human immunodeficiency virus.

Aasa-Chapman MM, Seymour CR, Williams I, McKnight A.

J Virol. 2006 Nov;80(21):10884-9.


Primary CCR5 only using HIV-1 isolates does not accurately represent the in vivo replicating quasi-species.

Aasa-Chapman MM, Aubin K, Williams I, McKnight A.

Virology. 2006 Aug 1;351(2):489-96. Epub 2006 May 19.


Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection.

Aasa-Chapman MM, Holuigue S, Aubin K, Wong M, Jones NA, Cornforth D, Pellegrino P, Newton P, Williams I, Borrow P, McKnight A.

J Virol. 2005 Mar;79(5):2823-30.


Development of the antibody response in acute HIV-1 infection.

Aasa-Chapman MM, Hayman A, Newton P, Cornforth D, Williams I, Borrow P, Balfe P, McKnight A.

AIDS. 2004 Feb 20;18(3):371-81.


Supplemental Content

Loading ...
Support Center